Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04254107
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : February 2, 2021
Sponsor:
Information provided by (Responsible Party):
Seagen Inc.

Brief Summary:

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas.

The study will have three parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with pembrolizumab works to treat solid tumors. Pembrolizumab is a drug that can be used to treat these types of cancer.


Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Gastric Carcinoma Gastroesophageal Junction Carcinoma Classical Hodgkin Lymphoma Diffuse Large B-cell Lymphoma Peripheral T-cell Lymphoma Cutaneous Melanoma Head and Neck Squamous Cell Carcinoma Bladder Cancer Ovarian Cancer Triple Negative Breast Cancer Drug: SEA-TGT Drug: pembrolizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 231 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Actual Study Start Date : May 29, 2020
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : March 31, 2023


Arm Intervention/treatment
Experimental: Monotherapy (Parts A and B) Drug: SEA-TGT
Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
Other Name: SGN-TGT

Experimental: Combination Therapy (Part C) Drug: SEA-TGT
Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
Other Name: SGN-TGT

Drug: pembrolizumab
Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle




Primary Outcome Measures :
  1. Number of participants with adverse events (AEs) [ Time Frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years ]
    To be summarized using descriptive statistics

  2. Number of participants with laboratory abnormalities by grade [ Time Frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years ]
    To be summarized using descriptive statistics

  3. Number of participants with a DLT at each dose level [ Time Frame: Up to 21 days ]
    To be summarized using descriptive statistics


Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to approximately 3 years ]
    Proportion of participants with complete response (CR) and partial response (PR) per the participant's specific tumor response criteria

  2. Complete response (CR) rate [ Time Frame: Up to approximately 3 years ]
    Proportion of participants with CR per the participant's specific tumor response criteria

  3. Duration of objective response [ Time Frame: Up to approximately 3 years ]
    Time from first response to the first documentation of disease progression or death due to any cause

  4. Duration of CR [ Time Frame: Up to approximately 3 years ]
    Time from start of the first documentation of CR to the first documentation of confirmed tumor progression or to death due to any cause, whichever comes first

  5. Duration of progression-free survival [ Time Frame: Up to approximately 3 years ]
    Time from first dose to the first documentation of disease progression or death due to any cause

  6. Duration of overall survival [ Time Frame: Up to approximately 3 years ]
    Time from start of study treatment to the date of death due to any cause

  7. Area under the concentration-time curve (AUC) [ Time Frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years ]
  8. Time to maximum concentration (Tmax) [ Time Frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years ]
  9. Maximum concentration (Cmax) [ Time Frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years ]
  10. Trough concentration (Ctrough) [ Time Frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years ]
  11. Number of participants with antidrug antibodies (ADA) [ Time Frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Monotherapy Inclusion Criteria (Parts A and B)

  • Histologically- or cytologically-confirmed advanced or metastatic malignancy, defined as:

    • One of the following disease indications:

      • Unresectable locally-advanced or metastatic NSCLC, gastric/gastroesophageal (GE) junction carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC), bladder cancer, ovarian cancer, or triple negative breast cancer (TNBC)
      • Lymphoma, including:

        • Classical Hodgkin lymphoma (cHL)
        • Diffuse large B-cell lymphoma (DLBCL)
        • Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)
      • Lymphoma: Participants should have disease progression on or after treatment with standard therapies expected to provide benefit in the judgement of the investigator.

        • cHL: Participants must have received at least 3 prior systemic therapies. Participants should have had disease recurrence or progression following brentuximab vedotin therapy or have been ineligible to receive brentuximab vedotin. Participants who have not received autologous stem cell transplant (SCT) must have refused or been deemed ineligible. Participants should have received or not be eligible to have received an anti-PD-1 agent.
        • DLBCL: Participants must have received at least 2 prior systemic chemo-immunotherapy regimens, including an anti-CD20 agent and combination chemotherapy. Unless clinically contraindicated, participants should have had disease that has relapsed after or be refractory to intensive salvage chemotherapy, including autologous SCT.
        • PTCL-NOS: Participants must have had at least 1 prior systemic therapy. Participants must have received or have been ineligible to receive the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy. Participants with CD30-positive disease must have received or be ineligible to receive brentuximab vedotin. Participants must have also received intensive salvage therapy (defined as combination chemotherapy ± autologous SCT) unless they refused or were deemed ineligible.
  • Measurable disease defined as:

    • Solid tumors: Measurable disease according to RECIST V1.1
    • Lymphomas: Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and measurable disease of ≥15 mm in the greatest transverse diameter by computed tomography (CT) scan, as assessed by the site radiologist.
  • A representative archival tumor tissue sample should be available as follows: Participants must provide archived tumor tissue, if available, from the most recent biopsy (≤24 months from screening). If archived tissue is not available, a fresh screening tumor biopsy will be requested for any participant enrolled in Part B whose tumors are considered accessible and appropriate in the opinion of the investigator.
  • ECOG Performance Status score of 0 or 1

Combination Inclusion Criteria (Part C)

  • Participants with a histologically-confirmed advanced NSCLC or gastric carcinoma meeting at least 1 of the following criteria:

    • Unresectable locally-advanced or metastatic
    • Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy
  • Measurable disease by CT or magnetic resonance imaging (MRI) as defined by RECIST V1.1
  • A representative tumor tissue sample should be available as follows: Participants must provide archived tumor tissue, if available, from the most recent biopsy (≤24 months from screening). If archived tissue is not available, a fresh screening tumor biopsy will be requested for any participant whose tumors are considered accessible and appropriate in the opinion of the investigator.
  • ECOG Performance Status score of 0 or 1

Monotherapy Exclusion Criteria (Parts A and B)

  • History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
  • Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment that has not been completed before the first dose of study drug within the timeframe as follows:

    • Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks

      • Palliative radiotherapy (≤2 weeks of radiotherapy to non-central nervous system [CNS] disease): ≤7 days prior to start of SEA-TGT
    • Immune-checkpoint inhibitors: 4 weeks
    • Monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression)
    • T-cell or other cell-based therapies: 12 weeks
  • Known CNS metastases

    • Participants with a history of CNS metastases are allowed if they have undergone treatment for the CNS disease, symptoms have resolved, and steroids have been discontinued.
    • Leptomeningeal involvement by malignant disease is excluded regardless of prior treatment.
  • Known hypersensitivity to any excipient contained in the drug formulation of SEA-TGT
  • Previous allogeneic SCT. Participants with prior autologous SCT may be eligible if they are >100 days from autologous SCT and fulfill all other inclusion criteria.
  • Prior use of any anti-TIGIT mAb.
  • Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg daily prednisone or equivalents are permitted in the absence of active immune disease.

Combination Exclusion Criteria (Part C)

  • History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
  • Previous therapy with an anti-PD-1 or anti-PD-L1 inhibitor.
  • Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment that has not been completed before the first dose of study drug within the timeframe as follows:

    • Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks

      • Palliative radiotherapy (≤2 weeks of radiotherapy to non-CNS disease): ≤7 days prior to start of SEA-TGT.
    • Immune-checkpoint inhibitors: 4 weeks
    • Monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression)
    • T-cell or other cell-based therapies: 12 weeks
  • Known active CNS metastases.

    • Participants with a history of CNS metastases are allowed if they have undergone treatment for the CNS disease, symptoms have resolved, and steroids have been discontinued.
    • Leptomeningeal involvement by malignant disease is excluded regardless of prior treatment.
  • Known hypersensitivity to any excipient contained in the drug formulation of SEA-TGT
  • Participants with active known or suspected autoimmune disease or significant autoimmune-related toxicity from prior immuno-oncology-based therapy (prior autoimmune colitis, pneumonitis, transaminitis); Participants with vitiligo, controlled type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Uncontrolled diabetes mellitus
  • History of interstitial lung disease
  • Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg daily prednisone or equivalents are permitted in the absence of active immune disease.
  • Prior use of any anti-TIGIT mAb

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04254107


Contacts
Layout table for location contacts
Contact: Seagen Trial Information Support 866-333-7436 clinicaltrials@seagen.com

Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35249
Contact: Jenny King       jpking@uabmc.edu   
Principal Investigator: Amitkumar Mehta         
United States, California
City of Hope National Medical Center Recruiting
Duarte, California, United States, 91010-3000
Principal Investigator: Jasmine Zain         
United States, Minnesota
Mayo Clinic Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Ashley Moyer    507-284-0923    Haeska.Ashley@mayo.edu   
Principal Investigator: Stephen Ansell         
United States, Oregon
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Lynn Freitas       lynn.freitas@providence.org   
Contact: Christina Lopez    503-215-5696    canrsrchstudies@providence.org   
Principal Investigator: Rachel Sanborn         
United States, Pennsylvania
Hillman Cancer Center / University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Barbara Stadterman    412-647-2811    stadtermanbm@upmc.edu   
Contact: Catherine Davis    412-647-2811    davisc20@upmc.edu   
Principal Investigator: Diwakar Davar         
France
Institut Gustave Roussy Recruiting
Villejuif, France, 94805
Contact: Seattle Genetics Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Vincent Vibrag         
Italy
Istituto Europeo di Oncologia Recruiting
Milan, Italy, 20141
Spain
Hospital Universitario Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Contact: Seattle Genetics Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
United Kingdom
The Royal Marsden Hospital (Surrey) Recruiting
Sutton, United Kingdom, SM2 5PT
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Anna Minchom         
Sponsors and Collaborators
Seagen Inc.
Investigators
Layout table for investigator information
Study Director: Andres Forero-Torres, MD Seagen Inc.
Layout table for additonal information
Responsible Party: Seagen Inc.
ClinicalTrials.gov Identifier: NCT04254107    
Other Study ID Numbers: SGNTGT-001
First Posted: February 5, 2020    Key Record Dates
Last Update Posted: February 2, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Seagen Inc.:
NSCLC
cHL
HNSCC
TNBC
DLBCL
PTCL-NOS
Seattle Genetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Carcinoma
Lymphoma, Large B-Cell, Diffuse
Triple Negative Breast Neoplasms
Squamous Cell Carcinoma of Head and Neck
Lymphoma, T-Cell, Peripheral
Stomach Neoplasms
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Site
Carcinoma, Squamous Cell
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Breast Neoplasms
Breast Diseases
Skin Diseases
Head and Neck Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Pembrolizumab
Antineoplastic Agents, Immunological